共 50 条
- [31] Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies HEADACHE, 2018, 58 : 165 - 166
- [34] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) (vol 20, 75, 2019) JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
- [37] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study The Journal of Headache and Pain, 2022, 23
- [38] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
- [40] 100% response rate to galcanezumab in patients with episodic migraine: randomized, double-blind, placebo-controlled studies JOURNAL OF HEADACHE AND PAIN, 2018, 19